PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
LGX818 for Patients With BRAFV600 Mutated Tumors
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01981187
- Locations
- 🇺🇸
Yale University School of Medicine Smilow Cancer Hospital, New Haven, Connecticut, United States
🇺🇸Whittingham Cancer Center Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Highlands Oncology Group Highlands Oncology Group (22), Fayetteville, Arkansas, United States
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: no intervention
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 605
- Registration Number
- NCT01981473
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Associates, P. C., Mesa, Arizona, United States
🇺🇸Phase III Clinical Research, Fall River, Massachusetts, United States
🇦🇷DIM Clinica Privada, Ramos Mejía, Ramos Mejía / Buenos Aires / Argentina, Argentina
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 686
- Registration Number
- NCT01976364
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇧🇪ZNA Jan Palfijn, Merksem, Belgium
🇧🇷Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS, Porto Alegre, RS, Brazil
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16784
- Registration Number
- NCT01975376
- Locations
- 🇺🇸
Optimed Research, LTD, Columbus, Ohio, United States
🇺🇸Intermed Group, Los Angeles, California, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10564
- Registration Number
- NCT01975389
- Locations
- 🇺🇸
Atlanta Center For Medical Research, Atlanta, Georgia, United States
🇺🇸Optimed Research, LTD, Columbus, Ohio, United States
🇺🇸LION Research, Norman, Oklahoma, United States
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
- Conditions
- ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 364
- Registration Number
- NCT01970865
- Locations
- 🇺🇸
Karmanos Center Institute, Detroit, Michigan, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Highlands Oncology Group/Research, Fayetteville, Arkansas, United States
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
- Conditions
- Hyperlipidemia
- Interventions
- Other: Placebo
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2139
- Registration Number
- NCT01968967
- Locations
- 🇺🇸
San Marcus Research Clinic, Inc., Miami, Florida, United States
🇺🇸Clinical Research of Miami, Miami, Florida, United States
🇺🇸Finlay Medical Research, Miami, Florida, United States
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Other: Placebo
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370
- Registration Number
- NCT01968980
- Locations
- 🇺🇸
IMD Medical Group, Los Angeles, California, United States
🇺🇸Galenos Research, Dallas, Texas, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
- Conditions
- Hyperlipidemia
- Interventions
- Other: Placebo
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 711
- Registration Number
- NCT01968954
- Locations
- 🇺🇸
Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States
🇺🇸Internal Medicine Associates, Eunice, Louisiana, United States
🇵🇱Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland
A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT01965600
- Locations
- 🇺🇸
(Drug Shipment Address ONLY) Duke University Health Systems (DUHS) Investigational Drug Services, Durham, North Carolina, United States
🇺🇸Duke Clinical Research Unit, Durham, North Carolina, United States